US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Algernon Pharmaceuticals Inc.

0.0475

-0.0004-0.84%

Volume:31.61K

Turnover:1.58K

Market Cap:1.30M

PE:- -

High:0.0500

Open:0.0500

Low:0.0475

Close:0.0479

52wk High:0.0900

52wk Low:0.0356

Shares:27.30M

Float Shares:27.30M

Volume Ratio:11.70

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

ROE:-94.93%

ROA:-23.08%

PB:1.03

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000

Press Release: Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AGNPF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGNPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGNPF\",,,,,undefined,":{"symbol":"AGNPF","market":"US","secType":"STK","nameCN":"Algernon Pharmaceuticals Inc.","latestPrice":0.0475,"timestamp":1755633600000,"preClose":0.0479,"halted":0,"volume":31612,"delay":15,"floatShares":27301200,"shares":27301200,"eps":0,"marketStatus":"Post-Mkt","change":-0.0004,"latestTime":"08-19 16:00:00 EDT Delay","open":0.05,"high":0.05,"low":0.0475,"amount":1577.9,"amplitude":0.052192,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1755648000000},"marketStatusCode":4,"adr":0,"exchange":"OTCQB","adjPreClose":0.0479,"volumeRatio":11.70468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGNPF\",,,,,undefined,":{"symbol":"AGNPF","floatShares":27301200,"roa":"-23.08%","roe":"-94.93%","lyrEps":0,"volumeRatio":11.70468,"shares":27301200,"dividePrice":0,"high":0.05,"amplitude":0.052192,"preClose":0.0479,"low":0.0475,"week52Low":0.0356,"pbRate":"1.03","week52High":0.09,"institutionHeld":0,"latestPrice":0.0475,"eps":0,"divideRate":0,"volume":31612,"delay":15,"open":0.05,"prevYearClose":0.0463,"prevWeekClose":0.0483,"prevMonthClose":0.0469,"prevQuarterClose":0.057,"fiveDayClose":0.0489,"twentyDayClose":0.036,"sixtyDayClose":0.067},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGNPF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-12-23","symbol":"AGNPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1734930000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-07-29","symbol":"AGNPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722225600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-12-29","symbol":"AGNPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1703826000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-03-03","symbol":"AGNPF","defaultRemindTime":1677853800000,"type":"split","dateTimestamp":1677819600000,"forFactor":1,"toFactor":4,"ratio":0.25},{"market":"US","date":"2021-11-24","symbol":"AGNPF","defaultRemindTime":1637764200000,"type":"split","dateTimestamp":1637730000000,"forFactor":100,"toFactor":1,"ratio":100}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGNPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGNPF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGNPF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548517043","title":"Press Release: Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2548517043","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548517043?lang=en_us&edition=fundamental","pubTime":"2025-07-01 05:29","pubTimestamp":1751318940,"startTime":"0","endTime":"0","summary":"NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Each Preferred Unit will consist of one preferred share in the capital of the Company  and one half Preferred Share purchase warrant . Each full Preferred Warrant will now entitle the holder to acquire one Preferred Share  at an exercise price of $1.50 per Preferred Warrant Share  for a period of twelve  months from the Issuance Date, after which on First Anniversary, the Preferred Exercise Price will increase to $2.50 per Preferred Warrant Share for a period of twelve  months from the First Anniversary, and on the Second Anniversary, the Preferred Exercise Price will increase to $5.00 per Preferred Warrant Share for a period of thirty-six  months from the Second Anniversary.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNPF"],"gpt_icon":0},{"id":"2537979548","title":"Press Release: Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2537979548","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537979548?lang=en_us&edition=fundamental","pubTime":"2025-05-23 08:50","pubTimestamp":1747961400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, May 22, 2025  -- Algernon Pharmaceuticals Inc.    , a Canadian healthcare and clinical stage drug development company, is pleased to announce it has closed the acquisition to acquire 100% of the issued and outstanding shares of NoBrainer Imaging Centers, Inc.   previously announced on May 13, 2025. The Transaction moves Algernon into the Alzheimer's Disease  diagnostic and treatment market, expanding on the Company's existing neurological research programs, and provides Algernon exclusive master franchise and licensing rights to open AD screening, diagnostic, and treatment centers across Canada and in multiple U.S. markets.Each Common Warrant entitles the holder thereof to purchase one  Common Share at an exercise price  of $0.15 per Common Share for a period of twelve  months from the issuance date , after which on the first anniversary of the Issuance Date , the Common Exercise Price will increase to $0.25 per Common Share for a period of twelve  months f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGNPF"],"gpt_icon":0},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNTM","DRUG","BK4202","BK4539","PHRRF","MDXXF","SILO","BK4168","SEEL","CMPS","ALID","FLHLF","SPRC","RLMD","IXHL","MIRA","GHRS","CMND","BK4007","ATAI","ENVB","SNPX","RVVTF","NUMIF","ENTBF","BK4547","NRXP","KTTA","AGNPF","MNMD","PBM","PSYGF","CYBN","BETRF","MYCOF","OPTHF","BK4139"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNMD","FLHLF","CMND","BK4168","SNPX","PSYGF","CMPS","SILO","AGNPF","SEEL","SPRC","BK4007","GHRS","QNTM","PHRRF","DRUG","BETRF","IXHL","RLMD","MIRA","NUMIF","CYBN","MDXXF","MYCOF","BK4547","ALID","PBM","OPTHF","ENTBF","BK4202","BK4539","NRXP","BK4139","KTTA","RVVTF","ATAI"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AGNPF\",params:#limit:6,delay:false,,,undefined,":[]}}